Natural products as promising drug candidates for the treatment of hepatitis B and C

Acta Pharmacologica Sinica

Volumn 30, Issue 1, 2009, Pages 25-30

  Wohlfarth, Carolin ^a   Efferth, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiviral agent; Chemotherapy; Drug resistance; Hepatitis B; Hepatitis C; Natural product; Pharmacognosy

Indexed keywords

1 DEOXYNOJIRIMYCIN; ADEFOVIR DIPIVOXIL; ALPHA GLUCOSIDASE; ALPHA INTERFERON; ARTEMISININ; ARTESUNATE; BENZOFURAN DERIVATIVE; CASTANOSPERMINE 6 BUTYRATE; CHELERYTHRINE; CHRYSOPHANIC ACID DERIVATIVE; CHRYSOPHANOL 8 O BETA DEXTRO GLUCOSIDE; CYCLOPHILIN; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DIHYDROCHELERYTHRINE; ELLAGIC ACID; ENTECAVIR; GUAIANOLIDE DERIVATIVE; LAMIVUDINE; MELLEIN; MONTIRELIN; PROTOSTANE TRITERPENE; PSEUDOGUAIANOLIDE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE; SAIKOSAPONIN C; TELBIVUDINE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; WOGONIN; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT;

ANEMIA; ANTIVIRAL ACTIVITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEMOLYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMPOTENCE; INTESTINAL BLEEDING; LEUKOPENIA; NEPHROTOXICITY; NONHUMAN; POINT MUTATION; REVIEW; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; LIVER DISEASE; PHYSIOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER DISEASES;

EID: 64849111443     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2008.5     Document Type: Review

References (40)

1. Qureshi SA. Hepatitis C virus - biology, host evasion strategies, and promising new therapies on the horizon. Med Res Rev 2007; 27: 353-73.
2. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953-60.
3. Safioleas M, Lygidakis NJ, Manti C. Hepatitis B today. Hepato-gastroen-terology 2007; 54: 545-8.
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Vir Hepat 2004; 11: 97-107.
5. Arbuthnot P, Longshaw V, Naidoo T, Weinberg MS. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat 2007; 14: 447-59.
6. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antiviral Ther 2004; 9: 1013-26.
7. Waters L, Nelson M. New therapeutic options for hepatitis C. Curr Opin Infect Dis 2006; 19: 615-22.
8. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
9. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, et al. Mutation rate of hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007; 132: 1757-66.
10. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007; 13: 5673-81.
11. Kartal ED, Alpat SN, Ozgunes I, Usluer G. Adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. Adv Ther 2007; 24: 963-71.
12. Zoulim F. Current data on the treatment of chronic hepatitis B. Presse Med 2008; 37: 287-93.
13. Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol 2007; 13: 1195-203.
14. De Francesco R, Migliaccio G. Challenges and successes in develop ing new therapies for hepatitis C. Nature 2005; 436: 953-60.
15. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antiviral Ther 2004; 9: 149-60.
16. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J Hepatol 2003; 39: 124-32.
17. Wu SF, Lee CJ, Liao CL, Dwek R, Zitzmann N, Lin YL. Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 2002; 76: 3596-604.
18. Jacob JR, Mansfield K, You JE, Tennant BC, Kim YH. Natural iminosugar derivatives of 1-deoxynojirimycin inhibit glycosylation of hepatitis viral envelope proteins. J Microbiol 2007; 45: 431-40.
19. Chapel C, Garcia C, Bartosch B, Roingeard P, Zitzmann N, Cosset FL, et al. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol 2007; 88: 1133-43.
20. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, et al. Antiviral effects of amantadine and imino-sugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330-8.
21. Dugourd D, Fenn J, Siu R, Coulson R, Clement JJ. Characterization of celgosivir, a clinical stage compound for the treatment of HCV infections. [Cited 8 Mar 2008.] Available from URL: htp:// www.migenix.com/annuals/ICAR- 2005-2.pdf
22. Sorbera LA, Castañ;er J, García-Capdevila L. Celgosivir. Drugs Fut 2005; 30: 545.
23. Doutre MS. Cyclosporin. Ann Dermatol Venereol 2002; 129: 392-404.
24. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007; 17: 245-52.
25. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111-22.
26. Zeisel MB, Baumert TF. Production of infectious hepatitis C virus in tissue culture: a breakthrough for basic and applied research. J Hepatol 2006; 44: 436-9.
27. Lee HY, Yum JH, Rho YK, Oh SJ, Choi HS, Chang HB, et al. Inhibition of HCV replicon cell growth by 2-arylbenzofuran derivatives isolated from Mori Cortex Radicis. Planta Med 2007; 73: 1481-5.
28. Dai J, Carté BK, Sidebottom PJ, Sek Yew AL, Ng S, Huang Y, et al. Circumdatin G, a new alkaloid from the fungus Aspergillus ochraceus. J Nat Prod 2001; 64: 125-6.
29. Hu JF, Patel R, Li B, Garo E, Hough GW, Goering MG, et al. Anti-HCV bioactivity of pseudoguaianolides from Parthenium hispitum. J Nat Prod 2007; 70: 604-7.
30. Huang RL, Chen CC, Huang HL, Chang CG, Chen CF, Chang C, et al. Anti-hepatitis B virus effects of wogonin isolated from Scutellaria baicalensis. Planta Med 2000; 66: 694-8.
31. Guo Q, Zhao L, You Q, Yang Y, Gu H, Song G, et al. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res 2007; 74: 16-24.
32. Shin MS, Kang EH, Lee YI. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 2005; 67: 163-8.
33. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990; 87: 6599-603.
34. Kang EH, Kown TY, Oh GT, Park WF, Park SI, Park SK, et al. The flavonoid ellagic acid from a medicinal herb inhibits host immune tolerance induced by the hepatitis B virus-e antigen. Antiviral Res 2006; 72: 100-6.
35. Romero MR, Efferth T, Serrano MA, Gastañ;o B, Macias RI, Briz O, et al. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res 2005; 68: 75-83.
36. Price R, van Vugt M, Phaipun L. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60: 547-55.
37. Li Z, Li LJ, Sun Y, Li J. Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy 2007; 53: 320-6.
38. Chiang LC, Ng LT, Liu LT, Shieh DE, Lin CC. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species. Planta Med 2003; 69: 705-9.
39. Jiang ZY, Zhang XM, Zhang FX, Liu N, Zhao F, Zhou J, et al. A new triterpene and anti-hepatitis B virus active compounds from Alisma orientalis. Planta Med 2006; 72: 951-4.
40. Wu YR, Ma YB, Zhao YX, Yao SY, Zhou J, Zhou Y, et al. Two new quaternary alkaloids and anti-hepatitis B virus active constituents from Corydalis saxicola. Planta Med 2007; 73: 787-91.